The study "Reducing MRI Use in Organised Prostate Cancer Testing Using Blood-Based Biomarkers - the OPT Stockholm3 Study" ...

Healthcare provider, LivingCare Group has been selected as the proposed imaging partner for the IMProVE clinical trial, a prostate cancer early-detection programme funded by Yorkshire Cancer Research.

AI-assisted imaging improved prostate cancer diagnosis and biopsy decision-making in new research presented at EAU 2026.

Read more about the factors that patients with prostate cancer value most in treatment decisions, as reported at EAU 2026.

Discover six prostate cancer companies advancing the next generation of therapies for all stages of the disease.

India, March 17 -- Latest study shows a serious link between emergency room wait times and patient survival. One in ten accident and emergency patients (A&E patients) with visible blood in urine ...

Let's see what is getting investors excited today. The post Why is this ASX 300 stock rocketing 17% today? appeared first on The Motley Fool Australia.

Large international study finds nearly half of patients admitted with visible blood in urine receive no imaging, delaying ...

(UroToday.com) The 2026 European Association of Urology (EAU) annual meeting featured a PARP inhibitors for prostate cancer session and a presentation by Dr. Himisha Beltran discussing how to read a ...

King’s College London surgeon performs the UK’s first remote robotic surgery, pioneering telesurgery and transforming patient care ...

The CAPTAIN trial shows faster recovery, fewer complications, and better early function with the minimally invasive therapy ...